BCAL Diagnostics Expands Avantect Testing Across National Pathology Networks

Highlights

• Avantect tests now accessible through Sonic and Healius networks.

• National rollout supports early detection of pancreatic and ovarian cancers.

• Expansion integrates advanced genomic and epigenomic analysis.

BCAL Diagnostics (BDX) extends Avantect test availability nationwide, enhancing early cancer detection through key pathology networks and advanced diagnostic tools.

Expanding Access to Life-Saving Diagnostics

BCAL Diagnostics (ASX:BDX) has accelerated the rollout of its Avantect Pancreatic and Ovarian blood tests, enhancing commercial availability across major pathology networks in Australia. The ASX 100 landscape has seen growing interest in companies advancing non-invasive diagnostic solutions, and BCAL is positioning itself at the forefront of early cancer detection.

Following an initial launch at Sydney Breast Clinic, the tests are now accessible through selected Sonic Healthcare collection centres in New South Wales, Queensland, and Victoria, as well as national coverage via the Healius Pathology Network. This broader availability ensures patients at elevated risk can access advanced testing conveniently.

Understanding Avantect Tests

Avantect is a cutting-edge cell-free DNA-based test designed to assist in the early detection of pancreatic and ovarian cancers. The latest generation of the test combines genomic and epigenomic analysis with sophisticated machine learning techniques, offering enhanced clinical insights for healthcare practitioners.

By leveraging such advanced technology, BCAL Diagnostics is contributing to improved patient outcomes, as early detection plays a critical role in providing treatment options at more effective stages of disease progression.

Strategic Collaborations with Pathology Networks

The expansion builds on BCAL's existing collaboration with Sonic Healthcare, already facilitating access to its breast cancer diagnostic, BREASTEST plus. The new agreements aim to increase the accessibility of blood-based cancer diagnostics in more routine clinical settings.

The inclusion of Sonic collection centres in key states allows targeted access in major population hubs, while the Healius agreement ensures national reach. These collaborations enable healthcare providers to integrate Avantect testing into standard patient pathways seamlessly.

Enhancing Early Detection Pathways

By embedding Avantect into established pathology networks, BCAL is moving beyond specialist clinics. The strategy supports earlier intervention for patients at higher risk, promoting proactive healthcare measures.

The integration of these diagnostic tools into broader clinical settings reflects a commitment to advancing early cancer detection in Australia. It also aligns with trends in ASX 200 companies investing in healthcare innovation and non-invasive diagnostics.

The Role of Advanced Diagnostic Technology

Avantect combines genomic and epigenomic markers with AI-driven analysis, providing healthcare practitioners with actionable insights. This approach exemplifies the increasing focus of ASX 300 companies on integrating data-driven technologies into patient care.

As healthcare systems worldwide emphasize early detection, BCAL Diagnostics is reinforcing its commitment to patient-centered innovation, ensuring high-risk patients can access vital diagnostics efficiently.

National Reach and Commercial Momentum

The rollout underscores BCAL’s strategic approach to commercial expansion. By leveraging the extensive networks of Sonic and Healius, the company is facilitating broader adoption of its non-invasive diagnostics across Australia.

This nationwide availability also positions BCAL Diagnostics as a leading contributor to the growing market for early detection tools, aligning with investor interest in ASX dividend stocks and healthcare innovation.